We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+1.31%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$204M
AUM Growth
-$3.68M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
97.39%
Holding
16
New
–
Increased
–
Reduced
–
Closed
–

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$104M 51.13%
6,068,125
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$23.6M 11.55%
1,115,352
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$21.5M 10.51%
1,025,000
– –
BMEA icon
4
Biomea Fusion
BMEA
$84.6M
$17.5M 8.59%
798,757
– –
GLUE icon
5
Monte Rosa Therapeutics
GLUE
$1.4B
$10.1M 4.94%
1,472,331
– –
OKUR
6
OnKure Therapeutics
OKUR
$154M
$5.81M 2.85%
88,608
– –
NUVB icon
7
Nuvation Bio
NUVB
$2.2B
$4.57M 2.24%
2,541,009
– –
ACRS icon
8
Aclaris Therapeutics
ACRS
$726M
$4.51M 2.21%
434,455
– –
ELEV
9
DELISTED
Elevation Oncology
ELEV
$4.31M 2.11%
2,834,910
– –
SPRB
10
Spruce Biosciences
SPRB
$118M
$2.59M 1.27%
16,073
– –
PSTX
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1.84M 0.9%
1,043,267
– –
MRKR icon
12
Marker Therapeutics
MRKR
$18.8M
$974K 0.48%
314,286
– –
TECX
13
Tectonic Therapeutic
TECX
$529M
$959K 0.47%
84,148
– –
SYRE icon
14
Spyre Therapeutics
SYRE
$8.54B
$762K 0.37%
67,646
– –
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$407K 0.2%
288,571
– –
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$380K 0.19%
387,653
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Aisling Capital Management held 16 positions worth $204M, down 1.8% from $208M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Trading was light in Q2 2023: portfolio turnover was 0%. Aisling Capital Management opened no new positions and made no exits, leaving the 16-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's ten largest holdings make up 97% of its $204M portfolio in Q2 2023.
  • Aisling Capital Management opened 0 new positions and closed 0 in Q2 2023.
  • Aisling Capital Management's portfolio value fell 1.8% quarter-over-quarter to $204M.

Based on Aisling Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.